Payment overview · 2025
General Payments
$1,188.38
39 reported records · 17 companies
Healthcare provider profile · identity verified
Edward Y C Chan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · SAN FRANCISCO, CA · NPI 1033155213
Verified facts
What the public records show
CMS Open Payments records show Edward Y C Chan, M.D. received $1,188.38 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tagrisso.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Tagrisso by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Promacta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $415.09 | 34.9% | 12 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.28 | 8.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $77.79 | 6.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $62.76 | 5.3% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.28 | 5.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $60.81 | 5.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $55.84 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.90 | 4.5% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $52.06 | 4.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $51.56 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.77 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.92 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.93 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.76 | 2.2% | 1 | 2025 |
| Coherus Oncology, Inc. | Unresolved — no canonical attribution shown | $22.17 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.14 | 1.9% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $19.32 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,095.39 | 38 |
| Education | $92.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $123.78 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $116.65 | 4 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $110.14 | 4 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $104.28 | 3 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $77.79 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $62.76 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.90 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $26.76 | 1 | 2025 |
Source payment records
|
|||||
| LOQTORZI Normalized: loqtorzi |
Biological | Coherus Oncology, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 93 | 28 |
| Tamoxifen Citrate | Tamoxifen Citrate | 84 | 24 |
| Losartan Potassium | Losartan Potassium | 80 | 23 |
| Anastrozole | Anastrozole | 77 | 24 |
| Tagrisso | Osimertinib Mesylate | 76 | suppressed |
| Metformin Hcl | Metformin Hcl | 73 | 21 |
| Hydroxyurea | Hydroxyurea | 66 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 54 | 17 |
| Prednisone | Prednisone | 42 | 13 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Promacta | Eltrombopag Olamine | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 16 |
| Abiraterone Acetate | Abiraterone Acetate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Erlotinib Hcl | Erlotinib Hcl | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Sorafenib | Sorafenib Tosylate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,188.38 · 39 records | AstraZeneca Pharmaceuticals LP | AKEEGA, BALVERSA, BRAFTOVI, CALQUENCE, Cologuard Collection Kit, ERLEADA, JAYPIRCA, KEYTRUDA, KISQALI, Kerendia, LIBTAYO, LOQTORZI, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, OPDIVO, Optune Lua (NovoTTF-200T), PYRUKYND, TAGRISSO, Vyloy, XALKORI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tagrisso play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error